公开(公告)号：US20230339882A1

公开(公告)日：2023-10-26

申请号：US18016144

申请日：2021-07-22

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Hao WU ,  Wenmao WU ,  Ling LI ,  Zhan ZHANG ,  Feng WANG ,  Ding YUAN ,  Yunfei WU ,  Qiang CHEN ,  Han HAN ,  Jing GUO ,  Hong LAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/04 ,  A61P35/00 ,  C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D491/107 ,  C07D471/10 ,  C07D513/10 ,  C07D498/10

CPC classification number: C07D401/04 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/10 ,  C07D491/107 ,  C07D498/10 ,  C07D513/10

Abstract: A compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treating an SHP2 mediation diseases. The compounds of formula I exerts an effect by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis.

公开(公告)号：US20230192705A1

公开(公告)日：2023-06-22

申请号：US18009277

申请日：2021-06-10

Applicant: Betta Pharmaceuticals Co., Ltd

Inventor： Bang FU ,  Zhongxin SUN ,  Xiaofeng XU ,  Wei REN ,  Yinlong LI ,  Ling LI ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07F9/6561 ,  C07D491/107 ,  A61P35/00 ,  A61P11/00 ,  A61P35/02

CPC classification number: C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07F9/6561 ,  C07D491/107 ,  A61P35/00 ,  A61P11/00 ,  A61P35/02

Abstract: Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

公开(公告)号：US20160137658A1

公开(公告)日：2016-05-19

申请号：US14896707

申请日：2014-06-09

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Shaojing Hu ,  Wei LONG ,  Fei WANG ,  Yinxiang WANG ,  Lieming DING

IPC: C07D491/056 ,  C07C57/145 ,  A61K31/519

CPC classification number: C07D491/056 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  C07B2200/13 ,  C07C57/145 ,  A61K2300/00

Abstract: Provided are Icotinib maleate (the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them.

Abstract translation: 提供马来酸伊西替尼（式I化合物）及其多晶型形式，以及制备和使用它们的方法。

公开(公告)号：US20240327518A1

公开(公告)日：2024-10-03

申请号：US18294516

申请日：2022-08-05

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Wenxin XU ,  Xuefei FANG ,  Deyu XU ,  Lieming DING

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68

CPC classification number: C07K16/2818 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569

Abstract: Provided are an anti-PD-L1 nanobody and use thereof. The anti-PD-L1 nanobody comprises a CDR1, a CDR2, and a CDR3, wherein the CDR1 comprises a sequence selected from SEQ ID NOs: 1, 5, and 9; the CDR2 comprises a sequence selected from SEQ ID NOs: 2, 6, and 10; and the CDR3 comprises a sequence selected from SEQ ID NOs: 3, 7, 11, and 14. The antibody can block the PD-1/PD-L1 and CD-80/PD-L1 signaling pathways, inhibit the growth of tumor cells, and exhibit a therapeutic effect against tumors.

公开(公告)号：US20240246994A1

公开(公告)日：2024-07-25

申请号：US18559682

申请日：2022-05-12

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Houxian ZU ,  Liang CHEN ,  Xizhen SONG ,  Xintao ZHAO ,  Kai CHEN ,  Xiaoyun LIU ,  Jin WANG ,  Zhifang XIA ,  Ying XU ,  Yuanzheng ZHOU ,  Lieming DING ,  Jiabing WANG

IPC: C07D498/04 ,  A61K31/553 ,  A61P35/00

CPC classification number: C07D498/04 ,  A61K31/553 ,  A61P35/00

Abstract: Disclosed are a polymorph of (S)-1-(2-((S)-3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide, a composition comprising the polymorph, a use method therefor and a preparation method therefor.

公开(公告)号：US20230321100A1

公开(公告)日：2023-10-12

申请号：US18044049

申请日：2021-09-06

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Hao WU ,  Xiaofeng YANG ,  Qisheng LIU ,  Han HAN ,  Jinhua LI ,  Yang LI ,  Feng JIANG ,  Cuiwen KUANG ,  Hongfeng XIA ,  Hongbo ZHANG ,  Hong LAN ,  Jiabing WANG ,  Lieming DING

IPC: A61K31/513 ,  A61K39/395 ,  C07D403/04 ,  C07D401/14 ,  C07D403/14

CPC classification number: A61K31/513 ,  A61K39/3955 ,  C07D403/04 ,  C07D401/14 ,  C07D403/14

Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition comprising the compound.

公开(公告)号：US20230219956A1

公开(公告)日：2023-07-13

申请号：US17605268

申请日：2020-04-20

Applicant: BETTA PHARMACEUTICALS CO.,LTD

Inventor： Hao WU ,  Yuan LU ,  Jun YU ,  Xiao ZHOU ,  Boyan LI ,  Jiangqi HE ,  Shuibiao FU ,  Rongwen YANG ,  Yabin LI ,  Chao WANG ,  Jiabing WANG ,  Hong LAN ,  Lieming DING

IPC: C07D471/10 ,  C07D519/00 ,  C07D487/10 ,  C07D401/14 ,  C07D451/04 ,  A61P35/00

CPC classification number: C07D471/10 ,  C07D519/00 ,  C07D487/10 ,  C07D401/14 ,  C07D451/04 ,  A61P35/00

Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound. (I)

公开(公告)号：US20230131025A1

公开(公告)日：2023-04-27

申请号：US17799234

申请日：2021-02-08

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Mengqiang LIU ,  Xiaodong SONG ,  Qichao SHEN ,  Guolong DU ,  Haitong SHENG ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/12 ,  C07D215/38 ,  A61P35/00 ,  C07D401/14 ,  C07D417/14

Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.

公开(公告)号：US20220064196A1

公开(公告)日：2022-03-03

申请号：US17422700

申请日：2020-01-14

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07F9/6561

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20210261552A1

公开(公告)日：2021-08-26

申请号：US16973335

申请日：2019-06-06

Applicant: Betta Pharmaceuticals Co., LTD

Inventor： Hao WU ,  Wei GU ,  Xiaojing TANG ,  Wei WANG ,  Bo ZHAN ,  Dongjie FENG ,  Yongxin KE ,  Zhongyan CHEN ,  Yifei SHEN ,  Wenmao WU ,  Xintao ZHAO ,  Hong LAN ,  Jiabing WANG ,  Lieming DING

IPC: C07D487/04 ,  A61P35/00 ,  C07D401/04 ,  C07D417/04 ,  C07D491/20 ,  C07D403/14 ,  C07D487/20 ,  C07D519/00 ,  C07D513/04

Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.